VEGFR2

FDA stop sign

Pharma

FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time

The FDA has declined to approve Hengrui and Elevar’s anti-PD-1/VEGFR combo in first-line liver cancer for a third time.

Angus Liu Jul 10, 2026 10:55am

Liver

FDA rejects Elevar, Hengrui's PD-1 combo

May 17, 2024 10:16am

clinical trial data CRO contract research health

Hutchmed's fruquintinib proves itself in gastric cancer

Nov 14, 2022 11:47am